Del Zompo F, Crouchet E, Ostyn T, Nehme Z, Messé M, Juehling F, Désert R, Vieira AT, Moehlin J, Nakib D, Andrews T, Perciani C, Chung S, Bader G, McGilvray I, Caime C, Scaravaglio M, Carbone M, Invernizzi P, Yaqub S, Folseraas T, Karlsen TH, Shankar G, Primeaux M, Dhawan P et al. (2025)
Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis
J Hepatol (in press)
DOI 10.1016/j.jhep.2025.08.005, PubMed 40846184

Sudmann TM, Jørstad ØK (2025)
På høy tid med individuell vurdering av kjøreevne
Tidsskr Nor Laegeforen, 145 (9)
DOI 10.4045/tidsskr.25.0413, PubMed 40844342

Nilsen DWT, Leon De La Fuente R, Gallo P, Naesgaard P, Dib Ashur S, Michelsen AE, Aukrust P, Staines H, Ueland T (2025)
Reply to: Letter to the editor: High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients
Int J Cardiol, 133807 (in press)
DOI 10.1016/j.ijcard.2025.133807, PubMed 40840598

Dwt N, Leon De La Fuente R, Gallo P, Naesgaard P, Dib Ashur S, Michelsen AE, Aukrust P, Staines H, Ueland T (2025)
Reply to: Letter regarding the study by Nilsen et al. on IL-1RA and 5-Year Mortality Risk: Redefining the Threshold for high admission levels of IL-1RA
Int J Cardiol, 133806 (in press)
DOI 10.1016/j.ijcard.2025.133806, PubMed 40840594